AZN Stock - AstraZeneca PLC
Unlock GoAI Insights for AZN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $54.07B | $45.81B | $44.35B | $37.42B | $26.62B |
| Gross Profit | $43.87B | $37.54B | $31.96B | $24.98B | $21.32B |
| Gross Margin | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% |
| Operating Income | $10.00B | $8.19B | $3.76B | $1.06B | $5.16B |
| Net Income | $7.04B | $5.96B | $3.29B | $112.00M | $3.20B |
| Net Margin | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% |
| EPS | $1.14 | $1.91 | $1.06 | $0.04 | $1.22 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Visit WebsiteEarnings History & Surprises
AZNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 5, 2026 | $1.09 | — | — | — |
Q4 2025 | Nov 6, 2025 | $1.14 | $1.19 | +4.4% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $1.09 | $1.09 | 0.0% | = MET |
Q2 2025 | Apr 29, 2025 | $1.10 | $1.24 | +12.7% | ✓ BEAT |
Q1 2025 | Feb 6, 2025 | $1.07 | $1.05 | -1.9% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $1.03 | $1.04 | +1.0% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $1.20 | $0.99 | -17.5% | ✗ MISS |
Q2 2024 | Apr 25, 2024 | $1.22 | $1.03 | -15.6% | ✗ MISS |
Q1 2024 | Feb 8, 2024 | $0.79 | $0.73 | -7.6% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $0.85 | $0.87 | +2.4% | ✓ BEAT |
Q3 2023 | Jul 28, 2023 | $0.95 | $1.08 | +13.7% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $1.07 | $0.96 | -10.3% | ✗ MISS |
Q1 2023 | Feb 9, 2023 | $0.67 | $0.69 | +3.0% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $0.72 | $0.84 | +16.7% | ✓ BEAT |
Q3 2022 | Jul 29, 2022 | $0.78 | $0.86 | +10.3% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | $0.86 | $0.95 | +10.5% | ✓ BEAT |
Q1 2022 | Feb 10, 2022 | $0.77 | $0.84 | +9.1% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $0.63 | $0.54 | -14.3% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $0.43 | $0.45 | +4.7% | ✓ BEAT |
Latest News
Frequently Asked Questions about AZN
What is AZN's current stock price?
What is the analyst price target for AZN?
What sector is AstraZeneca PLC in?
What is AZN's market cap?
Does AZN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AZN for comparison